Glial fibrillary acidic protein in tumor types with cartilaginous differentiation. 2009

Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
Department of Pathology, Hospital do Cancer de Barretos, Barretos, SP, Brazil.

Glial fibrillary acidic protein (GFAP) is a member of the intermediary filament protein family. It is an important component of astrocytes and a known diagnostic marker of glial differentiation. GFAP is expressed in other neural tumors and pleomorphic adenoma and, less frequently, in cartilage tumors, chordomas, and soft tissue myoepitheliomas. The aim of this study was to evaluate the role of GFAP and its reliability in nonglial tumors as an immunohistochemical marker. We evaluated GFAP gene and protein expression using Q-PCR and immunohistochemistry, respectively, in 81 and 387 cases of soft tissue, bone tumors, and salivary pleomorphic adenomas. Immunohistochemistry staining for GFAP was observed in all osteosarcomas (8 cases), all pleomorphic adenomas (7 cases), in 5 of 6 soft tissue myoepitheliomas, and in 21 of 76 chondrosarcomas. By Q-PCR, GFAP was highly expressed in pleomorphic adenomas and, to a lesser extent, chondrosarcomas, soft tissue myoepitheliomas, and chondroblastic osteosarcomas. The results that we obtained by immunohistochemistry and Q-PCR were well correlated. GFAP is a potential marker for tumors with cartilaginous differentiation, supported by evidence that GFAP is expressed in certain cases of myoepithelial tumors by immunohistochemistry, including soft tissue myoepitheliomas, which are related to cartilaginous differentiation. These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008949 Adenoma, Pleomorphic A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed) Mixed Salivary Gland Tumor,Salivary Gland Tumor, Mixed,Syringoma, Chondroid,Adenomas, Pleomorphic,Chondroid Syringoma,Chondroid Syringomas,Pleomorphic Adenoma,Pleomorphic Adenomas,Syringomas, Chondroid
D009208 Myoepithelioma A usually benign tumor made up predominantly of myoepithelial cells. Myoepithelial Tumor,Myoepithelial Tumors,Myoepitheliomas,Tumor, Myoepithelial,Tumors, Myoepithelial
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D001859 Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES. Bone Cancer,Cancer of Bone,Cancer of the Bone,Neoplasms, Bone,Bone Neoplasm,Neoplasm, Bone
D002356 Cartilage A non-vascular form of connective tissue composed of CHONDROCYTES embedded in a matrix that includes CHONDROITIN SULFATE and various types of FIBRILLAR COLLAGEN. There are three major types: HYALINE CARTILAGE; FIBROCARTILAGE; and ELASTIC CARTILAGE. Cartilages
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D005904 Glial Fibrillary Acidic Protein An intermediate filament protein found only in glial cells or cells of glial origin. MW 51,000. Glial Intermediate Filament Protein,Astroprotein,GFA-Protein,Glial Fibrillary Acid Protein,GFA Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012468 Salivary Gland Neoplasms Tumors or cancer of the SALIVARY GLANDS. Cancer of Salivary Gland,Non-Sebaceous Lymphadenomas,Salivary Gland Cancer,Salivary Gland Lymphadenomas,Sebaceous Lymphadenomas,Cancer of the Salivary Gland,Neoplasms, Salivary Gland,Cancer, Salivary Gland,Cancers, Salivary Gland,Gland Neoplasm, Salivary,Gland Neoplasms, Salivary,Lymphadenoma, Non-Sebaceous,Lymphadenoma, Salivary Gland,Lymphadenoma, Sebaceous,Lymphadenomas, Non-Sebaceous,Lymphadenomas, Salivary Gland,Lymphadenomas, Sebaceous,Neoplasm, Salivary Gland,Non Sebaceous Lymphadenomas,Non-Sebaceous Lymphadenoma,Salivary Gland Cancers,Salivary Gland Lymphadenoma,Salivary Gland Neoplasm,Sebaceous Lymphadenoma

Related Publications

Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
September 1991, Presse medicale (Paris, France : 1983),
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
January 1981, Acta neuropathologica,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
January 1985, Acta neuropathologica,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
March 1982, Journal of the neurological sciences,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
February 1999, Neurochemical research,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
September 1990, Cancer,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
January 1989, Acta neuropathologica,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
May 2002, Current protocols in toxicology,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
June 2019, Current opinion in neurology,
Giscle Caravina Santos, and Kátia Candido Carvalho, and Roberto Falzoni, and Ana Carolina Q Simoes, and Rafael Malagoli Rocha, and Ademar Lopes, and Jose Vassallo, and Luiz Fernando Lima Reis, and Fernando Augusto Soares, and Isabela Werneck da Cunha
January 2023, Neurology India,
Copied contents to your clipboard!